---
title: "MaxCyte, Inc. (MXCT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MXCT.US.md"
symbol: "MXCT.US"
name: "MaxCyte, Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-19T21:38:11.326Z"
locales:
  - [en](https://longbridge.com/en/quote/MXCT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MXCT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MXCT.US.md)
---

# MaxCyte, Inc. (MXCT.US)

## Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.maxcyte.com](https://www.maxcyte.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.61)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 51 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -14.30% |  |
| Net Profit YoY | 6.39% |  |
| P/B Ratio | 0.68 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 113548972.32 |  |
| Revenue | 32287000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -21.30% | E |
| Profit Margin | -121.16% | E |
| Gross Margin | 83.74% | A |
| Revenue YoY | -14.30% | E |
| Net Profit YoY | 6.39% | C |
| Total Assets YoY | -15.43% | E |
| Net Assets YoY | -15.81% | E |
| Cash Flow Margin | 72.01% | C |
| OCF YoY | -14.30% | E |
| Turnover | 0.15 | D |
| Gearing Ratio | 13.67% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - MaxCyte, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-14.30%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "6.39%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.68",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "113548972.32",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "32287000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-21.30%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-121.16%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "83.74%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-14.30%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "6.39%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-15.43%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-15.81%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "72.01%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-14.30%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.15",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.67%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -2.90 | 36/59 | - | - | - |
| PB | 0.68 | 7/59 | 1.10 | 0.86 | 0.51 |
| PS (TTM) | 3.52 | 28/59 | 5.82 | 4.56 | 2.69 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 71% |
| Hold | 2 | 29% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.04 |
| Highest Target | 5.00 |
| Lowest Target | 2.43 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MXCT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MXCT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MXCT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MXCT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**